The Press Room

In an interview with Michigan Oncology Quality Consortium's Ovarian Cancer Education Podcast, Radhika Gogoi, M.D., member of the Gynecologic Multidisciplinary Team at Karmanos, discusses a new diagnosis and the basics of ovarian cancer. "We recommend that all women who are diagnosed with ovarian cancer go through genetic testing to determine whether they carry a gene that puts them at higher risk for ovary and breast cancer. If they are positive, their family members or relatives should also seek geneti...

The Barbara Ann Karmanos Cancer Institute is pleased to announce that its National Cancer Institute (NCI) Core Grant has been renewed. This renewal extends Karmanos’ prestigious NCI designation through 2025. Karmanos is among 51 centers nationwide to receive this designation. NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. They play a vital role in advancing towards the goal of ...

From patientpower.info Erlene Seymour, M.D., hematology oncologist at Karmanos Cancer Institute joined Patient Power Co-Founder Andrew Schorr to explain diagnosing advanced DLBCL, the standard therapy R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) and the new medications that are being used in combination with R-CHOP.

Often called the “forgotten cancer,” sarcoma refers to more than 70 subtypes of cancer that affect the body’s connective tissue. "Sarcomas are rare. There are less than 13,000 soft tissue sarcoma diagnoses per year, so it affects a smaller population than some other cancers, such as breast cancer,” explained Alysia Kemp, M.D., leader of the Sarcoma Multidisciplinary Team at the Barbara Ann Karmanos Cancer Institute. “Because it’s rare, less than one percent of all cancer diagnoses, there isn’t as much a...

From The Cancer Letter Four cancer centers were due for NCI Cancer Center Support Grant site visits in May, including Karmanos Cancer Institute. All four institutions decided to proceed with the virtual option instead of delaying the Cancer Center Support Grant site visits to the fall. The Cancer Letter details the experience of these institutions. Click here to read the complete article.

From Wayne State University School of Medicine News Karmanos Cancer Institute President & CEO Gerold Bepler, M.D., Ph.D., was recognized by Crain’s Detroit Business as Health Care Heroes in the magazine’s June 1 edition. Dr. Bepler was recognized in the administrator/executive category. Click here to read the complete article.

From FOX 47 News Beth Layhe, D.O., oncologist, Karmanos Cancer Institute at McLaren Greater Lansing explains what to look for when it comes to melanoma and a concerning spot. The story was published in recognition of May, which was National Skin Cancer Awareness Month. Click here to read the complete article.

After nearly 18 months of hard work and an almost 2,000-page grant application, Karmanos had a successful core grant site visit on May 7, 2020. Due to COVID-19, this year’s visit was unique because it was virtual. During these extraordinary times of the coronavirus emergency, the NIH has mandated that there be no face-to-face peer review meetings and recommended an alternative review formats (video conferencing or virtual meeting). Karmanos was one of the first four cancer centers to engage in a virtual...

From WDET, 101.9 FM Jeffrey Zonder, M.D., leader of the Multiple Myeloma Multidisciplinary Team at Karmanos Cancer Institute, talks with Russ McNamara about an upcoming Clinical Trial for a COVID-19 treatment at Karmanos. Researchers at Karmanos participated in the development of this drug, which has been FDA approved for the treatment of multiple myeloma. Now, Karmanos is participating in clinical trials testing this drug for the treatment of COVID-19. Click here to listen to the complete story on WDET...

Elisabeth Heath, M.D., FACP, was highlighted in news from the Department of Defense’s Prostate Cancer Research Program for her work addressing the health care needs of populations disproportionately affected with prostate cancer. The Barbara Ann Karmanos Cancer Institute had a minority accrual rate of 42 percent in prostate cancer clinical trials. Read the full article here .